A phase 1b study of 30-minute infusion carfilzomib 20/45 and 20/56 mg/m2plus 40 mg weekly dexamethasone in patients with relapsed and/or refractory (r/r) multiple myeloma

Authors
Category Primary study
JournalBlood
Year 2012
This article has no abstract
Epistemonikos ID: 36450a1256e0a5e26b2c9cc9a148f1dabec0899b
First added on: Feb 05, 2025